Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
05:53:29 EDT Tue 25 Mar 2025
Enter Symbol
or Name
USA
CA



Forgot password?
Trouble logging in?
Login ID:
Password:
Save

Q:MNKD - MANNKIND CORPORATION - https://www.mannkindcorp.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
MNKD - Q0.14.59·5.400.25.23+0.010.21,323.96,6945,6035.23  5.28  5.207.62  3.97Mar 24Mar 1015 min RT 2¢

Recent Trades - Last 10 of 5603
Time ETExPriceChangeVolume
     
     
     
     
     
     
     
     
     
     

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2025-03-10 06:05U:MNKDNews ReleaseMannKind Showcases Efficacy, Safety, and Mealtime Control Data from Recent Pediatric and Adult Studies of Afrezza(TM) at the ATTD Conference, March 19-22
2025-02-26 16:05U:MNKDNews ReleaseMannKind Corporation Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
2025-02-19 16:05U:MNKDNews ReleaseMannKind Corporation to Hold 2024 Fourth Quarter and Full Year Financial Results Conference Call on February 26, 2025
2025-02-06 16:05U:MNKDNews ReleaseMannKind to Present at Upcoming Investor Conferences
2025-01-06 16:30U:MNKDNews ReleaseMannKind Expands Executive Leadership Team
2024-12-18 07:00U:MNKDNews ReleaseMannKind Corporation Announces Exchange of Convertible Notes for Stock and Cash
2024-12-16 06:05U:MNKDNews ReleaseMannKind Announces Six-Month Results From Phase 3 INHALE-1 Pediatric Diabetes Trial Utilizing Inhaled Insulin (Afrezza(TM))
2024-12-11 06:00U:MNKDNews ReleaseCDSCO Approves Afrezza(TM) (insulin human) Inhalation Powder in India
2024-11-07 16:02U:MNKDNews ReleaseMannKind Corporation Reports 2024 Third Quarter Financial Results and Provides Business Update
2024-11-05 16:15U:MNKDNews ReleaseMannKind to Present at 2024 UBS Healthcare Conference
2024-11-04 06:05U:MNKDNews ReleaseMannKind Successfully Completes Phase 1 Trial of Nintedanib DPI for Pulmonary Fibrotic Diseases
2024-10-31 16:05U:MNKDNews ReleaseMannKind Corporation to Hold 2024 Third Quarter Financial Results Conference Call on November 7, 2024
2024-09-30 06:00U:MNKDNews ReleaseMore Adults With Type 1 Diabetes Achieved A1C Goal (<7%) After Switching From Multiple Daily Insulin Injections or Automated Pumps to Inhaled Insulin (Afrezza(TM))
2024-09-18 06:15U:MNKDNews ReleaseMannKind Announces Clearance from PMDA to Initiate Phase 3 Clinical Trial (ICoN-1) in Japan Evaluating Clofazimine Inhalation Suspension for the Treatment of Nontuberculous Mycobacterial (NTM) Lung Disease
2024-09-10 16:30U:MNKDNews ReleaseMannKind to Present at 2024 Cantor Fitzgerald Global Healthcare Conference
2024-08-27 16:30U:MNKDNews ReleaseMannKind to Present at Upcoming Conferences
2024-08-14 08:00U:MNKDNews ReleaseKent Kresa to Retire from MannKind's Board of Directors; Steven B. Binder to be Appointed to the Board
2024-08-07 08:00U:MNKDNews ReleaseMannKind Corporation Reports 2024 Second Quarter Financial Results: Provides Clinical Development Update
2024-07-31 06:30U:MNKDNews ReleaseMannKind Launches Educational Website to Raise Awareness of NTM Lung Disease
2024-07-30 16:30U:MNKDNews ReleaseMannKind Corporation to Hold 2024 Second Quarter Financial Results Conference Call on August 7, 2024